Lipid metabolism in patients with hematologic cancers

It is considered that hypercholesterolemia is life-threatening and low cholesterol levels are a positive factor. However, taking into consideration the fact that cholesterol plays a key role in cell proliferation, it should be remembered that its low blood level may be linked to high cholesterol dem...

Full description

Bibliographic Details
Main Authors: S G Vladimirova, L N Tarasova
Format: Article
Language:Russian
Published: "Consilium Medicum" Publishing house 2016-03-01
Series:Терапевтический архив
Subjects:
Online Access:https://ter-arkhiv.ru/0040-3660/article/viewFile/31960/pdf
id doaj-9a607dd63fd047b99acbfe0452dec144
record_format Article
spelling doaj-9a607dd63fd047b99acbfe0452dec1442020-11-25T03:23:07Zrus"Consilium Medicum" Publishing houseТерапевтический архив0040-36602309-53422016-03-0188311612028976Lipid metabolism in patients with hematologic cancersS G VladimirovaL N TarasovaIt is considered that hypercholesterolemia is life-threatening and low cholesterol levels are a positive factor. However, taking into consideration the fact that cholesterol plays a key role in cell proliferation, it should be remembered that its low blood level may be linked to high cholesterol demands from neoplastic cells. The literature review analyzes the results of recent investigations of lipid metabolism in patients with hematologic cancers and their other types. All given investigations show a significant reduction in the serum levels of total cholesterol and high-density lipoproteins in patients with hematological disease at its onset. The data for other indicators of the lipid transport system are ambiguous. Such changes have been elucidated to be associated with the accumulation of cholesterol in the leukemia cells due to enhanced synthesis de novo, a more active absorption from circulation and blocked release of its surplus. If the disease runs a favorable course, lipid metabolic parameters become normalized and, in case of remission, correspond to those seen in healthy individuals. They continue to decline in patients with disease progression. This allows the consideration of cholesterol, its fractions, and apolipoproteins as biochemical prognostic markers in hematological cancer patients and as indicators for assessment of treatment results. In addition, there is evidence for the effect of chemotherapeutic agents on lipid metabolism. Recent attempts to elaborate new treatment strategies, by using the current knowledge on the role of lipid metabolism in cancers, are considered.https://ter-arkhiv.ru/0040-3660/article/viewFile/31960/pdflipid metabolismcholesterollipoproteinshematological cancersacute leukemias
collection DOAJ
language Russian
format Article
sources DOAJ
author S G Vladimirova
L N Tarasova
spellingShingle S G Vladimirova
L N Tarasova
Lipid metabolism in patients with hematologic cancers
Терапевтический архив
lipid metabolism
cholesterol
lipoproteins
hematological cancers
acute leukemias
author_facet S G Vladimirova
L N Tarasova
author_sort S G Vladimirova
title Lipid metabolism in patients with hematologic cancers
title_short Lipid metabolism in patients with hematologic cancers
title_full Lipid metabolism in patients with hematologic cancers
title_fullStr Lipid metabolism in patients with hematologic cancers
title_full_unstemmed Lipid metabolism in patients with hematologic cancers
title_sort lipid metabolism in patients with hematologic cancers
publisher "Consilium Medicum" Publishing house
series Терапевтический архив
issn 0040-3660
2309-5342
publishDate 2016-03-01
description It is considered that hypercholesterolemia is life-threatening and low cholesterol levels are a positive factor. However, taking into consideration the fact that cholesterol plays a key role in cell proliferation, it should be remembered that its low blood level may be linked to high cholesterol demands from neoplastic cells. The literature review analyzes the results of recent investigations of lipid metabolism in patients with hematologic cancers and their other types. All given investigations show a significant reduction in the serum levels of total cholesterol and high-density lipoproteins in patients with hematological disease at its onset. The data for other indicators of the lipid transport system are ambiguous. Such changes have been elucidated to be associated with the accumulation of cholesterol in the leukemia cells due to enhanced synthesis de novo, a more active absorption from circulation and blocked release of its surplus. If the disease runs a favorable course, lipid metabolic parameters become normalized and, in case of remission, correspond to those seen in healthy individuals. They continue to decline in patients with disease progression. This allows the consideration of cholesterol, its fractions, and apolipoproteins as biochemical prognostic markers in hematological cancer patients and as indicators for assessment of treatment results. In addition, there is evidence for the effect of chemotherapeutic agents on lipid metabolism. Recent attempts to elaborate new treatment strategies, by using the current knowledge on the role of lipid metabolism in cancers, are considered.
topic lipid metabolism
cholesterol
lipoproteins
hematological cancers
acute leukemias
url https://ter-arkhiv.ru/0040-3660/article/viewFile/31960/pdf
work_keys_str_mv AT sgvladimirova lipidmetabolisminpatientswithhematologiccancers
AT lntarasova lipidmetabolisminpatientswithhematologiccancers
_version_ 1724607684238376960